These discrepant findings may also provide an explanation for our observation that there were no statistically significant differences between the effects of OCT, PAS or CAB on PRL secretion by prolactinomas from DA resistant patients and from patients operated for other reasons. The gene discussed is PLXNA2; the disease is prolactin-producing pituitary gland adenoma.